Washington
Q3 2026 · filed Oct 19Lobbying Q3 $20K n/a QoQ
YoY +100.0% vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
MMMMedicare/Medicaid
8 quarters Open in Washington ›
COCH
Envoy Medical, Inc.$5.97 −0.53 (−8.15%)
Oct 27 4:00 PM ET · prev $6.50
Market cap
$46.0M
Nano cap
Consensus
Buy
88% Buy or better · 8 analysts
Median target
$20.00
+235% · range $20.00–25.00
Next earnings
Nov 18
in 22 days
1 year
−26.3%
from $8.10 · Oct 27
30 days
−13.7%
from $6.92
52-week range
$3.90–9.01
−34% from high · low Feb 10
Avg volume 20D
13.2K
Oct 23 spike 69.3K
Short interest
🔒 Subscribers only
Insider net
+$8.2M
6 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 18, 2026
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- B Feb 12 6 insiders buy $8.2M at $0.1538
- R Jun 17 Envoy Medical's Form S-1 (File No. 333-290927) became effective on J…
- X Aug 31 Short interest falls 30.0% to 605.8K
- A Oct 6 Lake Street initiates
- E Oct 23 Trading halt: Trading Halt: COCH — T1 (News Pending)
- E Oct 26 Trading halt: Halt Resumed: COCH — trading resumed after LUDP (Volatilit…
- E Oct 26 Trading halt: Trading Halt: COCH — LUDP (Volatility Trading Pause)
- E Oct 26 Trading halt: Halt Resumed: COCH — trading resumed after T3 (News and Re…
Signal stack
Where each data set points today.
- InsidersBULLISH
6 insiders bought $8.2M. No open-market sales.
- InstitutionsMIXED
Q2 2026: 3 added (0 new), 1 trimmed or exited.
- AnalystsBULLISH
7 of 8 rate it Buy or better. Every target is above the price.
- TrendDOWNTREND
13% below its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| Focus Partners Wealth | DOUBLED | $336.8K |
| UBS Group AG | DOUBLED | $151.1K |
| LPL Financial LLC | ADD | $38.3K |
| BlackRock, Inc. | NEAR_EXIT | $4.2K |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $347.1K |
| MORGAN STANLEY | ADD | $49.2K |
| UBS Group AG | DOUBLED | $46.9K |
| CITIGROUP INC | DOUBLED | $143.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
8 analysts 88% rate it Buy or better
12-month targets · 3 analysts
$5.97 $20.00 $20.00 $25.00
Price is below the lowest target. Median implies +235%.Targets as of Oct 27, 2026.
Recent actions
| Date | Firm | Rating |
|---|---|---|
| Oct 6, 2026 | Lake Street INITIATE | Buy |
| Aug 21, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Jul 27, 2026 | LUCID CAPITAL MARKETS INITIATE | Buy |
| Jul 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4$8.2M
bought · 6 insiders
$0
sold · 0 insiders
| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 24, 2026 | Potashnick Robert CAO & VP of Finance | AWARD | 250,000 sh |
| Jun 19, 2026 | Lucas Brent T. Chief Executive Officer | AWARD | 1,000,000 sh |
| Jun 19, 2026 | Lucas Brent T. Chief Executive Officer | AWARD | 1,000,000 sh |
| May 29, 2026 | Lucas Brent T. Chief Executive Officer | AWARD | $19.7K |
| Apr 15, 2026 | McKhann Chas Director | AWARD | 100,000 sh |
| Feb 12, 2026 | Kantor Susan Director | BUY | 96,150 sh |
| Feb 12, 2026 | Lucas Brent T. Chief Executive Officer | BUY | 37,500 sh |
| Feb 12, 2026 | Potashnick Robert Interim CFO | BUY | 127,500 sh |
Earnings setup
EstimatesNov 18
reports in 22 days
Revision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Trading halts
| Oct 26, 2026 | 🔒 Fresh data, subscribers only | |
| Oct 26, 2026 | Volatility Pause | Resumed |
| Oct 23, 2026 | Resumption Scheduled | Resumed |
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 26, 2026 Trading halt
Oct 7, 2026 SEC 🔒 Fresh data, subscribers only
Envoy Medical settled a Delaware Chancery lawsuit with Atlas Merchant Capital SPAC Fund I LP, which alleged it was…
8-K — Impact 3/10
Envoy Medical filed definitive additional proxy materials (DEFA14A) for a special meeting on October 12, 2026, seeking…
DEFA14A — Impact 3/10
Aug 24, 2026 Insider
Potashnick Robert was granted 250,000 shares
CAO & VP of Finance
Jun 30, 2026 Inst.
Focus Partners Wealth — DOUBLED
425,310 shares ($336.8K)
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
190,838 shares ($151.1K)
Jun 19, 2026 Insider
Lucas Brent T. was granted 1,000,000 shares
Chief Executive Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Oct 26, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 26, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 26, 2026
Trading halt
Halt Resumed: COCH — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-26T13:33:15.000Z | Resumed 2026-10-26T13:38:15.000Z
Oct 26, 2026
Trading halt
Trading Halt: COCH — LUDP (Volatility Trading Pause)
Envoy Medical, Inc. | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Oct 26, 2026
Trading halt
Halt Resumed: COCH — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-23T23:50:00.000Z | Resumed 2026-10-26T13:00:00.000Z
SecBot reports
6 filings · 1 bullish · 2 bearish · 3 neutral- BEARISH 8-KOct 27, 2026
Envoy Medical filed a certificate of amendment to effect a 1-for-10 reverse stock split of its Class A common stock, effective October 26, 2026. The split is intended to maintain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KOct 7, 2026
Envoy Medical settled a Delaware Chancery lawsuit with Atlas Merchant Capital SPAC Fund I LP…
Litigation risk removed without cost — monitor for any residual SPAC-related claims or derivative actions that may surface. No immediate earnings or operational catalyst.
- NEUTRAL DEFA14ASep 2, 2026
Envoy Medical filed definitive additional proxy materials (DEFA14A) for a special meeting on…
Monitor the special meeting outcome on October 12 for reverse split approval; if passed, watch for Board's decision on exact split ratio and timing before year-end, which could affect Nasdaq listing…
- NEUTRAL 8-KAug 10, 2026
Envoy Medical reported Q2 2026 results with a slim net revenue of $51K (down from $78K YoY), a net…
The FDA PMA submission cadence (modules expected through Q2 2027) sets a clear catalyst timeline. Monitor for completion of all four modules and FDA feedback, which could trigger major price moves…
All COCH filing & press-release reports (6)
- 8-K reportOct 27, 2026
- 8-K reportOct 7, 2026
- DEFA14A reportSep 2, 2026
- 8-K reportAug 10, 2026
- 8-K reportJun 30, 2026
- EFFECT reportJun 17, 2026